| Identification | Back Directory | [Name]
Tilomisole | [CAS]
58433-11-7 | [Synonyms]
Tilomisole
Thiazolo[3,2-a]benzimidazole-2-acetic acid, 3-(4-chlorophenyl)- | [Molecular Formula]
C17H11ClN2O2S | [MOL File]
58433-11-7.mol | [Molecular Weight]
342.8 |
| Hazard Information | Back Directory | [Uses]
Tilomisole (Wy 18251) is a benzimidazothiazole experimental agent with anti-inflammatory activity. Tilomisole causes less agranulocytosis than levamisole, but retains immunomodulating capabilities. Tilomisole is orally active. Tilomisole has the potential for the research of cancer and inflammation[1][2]. | [References]
[1] Dillman RO, et al. WY 18,251 (Tilomisole), an analog of levamisole: tolerability, and immune modulating effects in cancer patients. Mol Biother. 1992;4(1):10-14. PMID:1385709
[2] Darwish SA, et al. New tilomisole-based benzimidazothiazole derivatives as anti-inflammatory agents: Synthesis, in vivo, in vitro evaluation, and in silico studies [published online ahead of print, 2022 Jan 29]. Bioorg Chem. 2022;120:105644. DOI:10.1016/j.bioorg.2022.105644 |
|
|